ST101

DRUG4 trials

Sponsors

Sonexa Therapeutics, Inc., Sapience Therapeutics

Conditions

Alzheimer's DiseaseBrain CancerBreast CancerEssential TremorGBMGlioblastomaGlioblastoma MultiformeMelanoma Recurrent

Phase 1

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruitingNCT04478279

Sapience TherapeuticsBrain Cancer, Breast Cancer, GBM +11

Start: 2020-07-01End: 2026-12-01Updated: 2026-02-09

Phase 2

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

CompletedNCT00842673

Sonexa Therapeutics, Inc.Alzheimer's Disease

Start: 2009-02-28End: 2010-09-30Updated: 2012-06-07

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

CompletedNCT00842816

Sonexa Therapeutics, Inc.Alzheimer's Disease

Start: 2009-02-28End: 2011-05-31Updated: 2012-06-07

A Pilot Efficacy and Safety Study of ST101 in Essential Tremor

CompletedNCT01332695

Sonexa Therapeutics, Inc.Essential Tremor

Start: 2011-04-30End: 2011-12-31Updated: 2012-01-06

Related Papers

Lucicebtide (ST101) plus chemoradiation in newly diagnosed GBM patients: Efficacy, pharmacodynamics, and safety from phase 2 window-of-opportunity study.

Journal of Clinical Oncology2026-05-27

Synergistic anti-tumor activity of EGFR inhibition and C/EBPβ antagonism in GBM.

bioRxiv (Cold Spring Harbor Laboratory)2026-04-21

Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.

Journal of Clinical Oncology2025-05-28

Abstract 839: The clinical C/EBPβ antagonist peptide lucicebtide synergizes with molecularly targeted therapies in GBM

Cancer Research2025-04-21

Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ.

Journal of Clinical Oncology2024-06-011 citations

Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms

Cancer Research2024-03-22

Abstract B038: Clinical and biological activity of ST101, a peptide antagonist of C/EBPβ, in recurrent Glioblastoma (rGBM) patients. Results from the rGBM cohort of a multi-cohort Phase 2 Study

Molecular Cancer Therapeutics2023-12-01

CTNI-44. NEOADJUVANT TREATMENT WITH ST101, C/EBPΒ ANTAGONIST, TRIGGERS NECROSIS AS A PATHOLOGICAL RESPONSE IN NEWLY DIAGNOSED GBM PATIENTS. TISSUE-BASED ANALYSIS FROM A SURGICAL WINDOW OF OPPORTUNITY TRIAL

Neuro-Oncology2023-11-01

Abstract LB236: ST101, a peptide antagonist of novel I/O target CEBPβ,reprograms MDSCs and promotes an immunoactive tumor microenvironment

Cancer Research2023-04-14

1173 ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses

Regular and Young Investigator Award Abstracts2022-11-01

Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.

Journal of Clinical Oncology2022-06-01